Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3385-3391

  Ramanathan, Ramesh K ^a,b   Trump, Donald L ^a,b   Eiseman, Julie L ^a,b   Belani, Chandra P ^a,b   Agarwala, Sanjiv S ^a,b   Zuhowski, Eleanor G ^a   Lan, Jing ^a   Potter, Douglas M ^a   Ivy, S Percy ^c   Ramalingam, Sakkaraiappan ^a,b   Brufsky, Adam M ^a,b   Wong, Michael K K ^a,b   Tutchko, Susan ^a   Egorin, Merrill J ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 AAG; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; CANCER INHIBITION; CLINICAL TRIAL; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; ODOR; PANCREATITIS; PERICARDIAL EFFUSION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; UNPLEASANT SENSATION; VOMITING; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BENZOQUINONES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FATIGUE; FEMALE; FOLLICLE STIMULATING HORMONE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROCORTISONE; LACTAMS, MACROCYCLIC; LEUKOCYTES, MONONUCLEAR; LEUKOPENIA; LUTEINIZING HORMONE; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROGESTERONE; PROTEIN-SERINE-THREONINE KINASES; RIFABUTIN; TESTOSTERONE; TREATMENT OUTCOME; VOMITING;

EID: 20944444881     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2322     Document Type: Article

References (32)

1. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
2. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
3. Ramanathan RK, Trump DL, Eiseman JL, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG) (NSC-704057) in patients with advanced tumors. Proc Am Soc Clin Oncol 2004; 24:202.
4. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23: 1078-87.
5. Banerji U, O'Donnel A, Scurr M, et al. A pharmacokinetically (PK)-pharmacodynamically (PD) guided phase I trial of the Heat Shock Protein 90 (HSP90) inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG). Proc Am Soc Clin Oncol 2003;22:199.
6. Grem JL, Morrison G, Guo X, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
7. Solit DB, Anana M, Valentin G, et al. Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 2003;22:198.
8. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93.
9. Barent RL, Nair SC, Carr DC, et al. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol Endocrinol 1998;12: 342-54.
10. Smith DF, Whitesell L, Nair SC, Chen S, Prapapanich V, Rimerman RA. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1995;15: 6804-12.
11. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
12. Smith DF, Sullivan WP, Marion TN, et al. Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70. Mol Cell Biol 1993;13:869-76.
13. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
14. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
15. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36. See: Sausville EA, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8.
16. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36. See: Sausville EA, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8.
17. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
18. Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg 2000; 70:1853-60.
19. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62:1559-66.
20. Investigator's brochure for 17-allylAminogeldanamycin(17-AAG). National Cancer Institute; 2004 Aug.
21. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice. Cancer Chemother Pharmacol 2001;47:291-302.
22. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998; 58:2385-96.
23. Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806-12.
24. An WG, Schnur RC, Neckers L, Blagosklonny MV. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997;40:60-4.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
26. Yeh KC, Kwan KC. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. Eur J Pharm Biopharm 1978;6: 79-98.
27. Rocci ML Jr, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983;16:203-16.
28. Eiseman JL, Lan J, Lagattuta TF, et al. Pharmacokinetics and Pharmacodynamics of 17-demethoxy 17-(2-dimethylamino)ethyl]amino]geldanamycin (NSC 707545) (17DMAG) in C.B-17 SCID Mice Bearing MDA-MB-231 Human Breast Cancer Xenografts. Cancer Chemother Pharmacol 2005;55: 21-32.
29. Zhang H, Chung D, Yang Y, et al. Identification of new biomarkers for clinical trials of hsp90 inhibitors. Proc Am Assoc Cancer Res 2004;45:894.
30. Wessinger NL, Kane SE. 17AAG combinations with conventional chemotherapeutic agents in two ovarian cancer cell lines. Proc Am Assoc Cancer Res 2002; 43:950-1.
31. Nguyen DM, Lorang D, Chen GA, Stewart JH, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371-8.
32. Solit DB, Egorin MJ, Valentin G, et al. Phase1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeldanamycin). Proc Am Soc Clin Oncol 2004;22:203.